Recent Advances in α-Synuclein Functions, Advanced Glycation, and Toxicity: Implications for Parkinson's Disease

被引:89
作者
Guerrero, Erika [1 ,4 ]
Vasudevaraju, P. [2 ]
Hegde, Muralidhar L. [3 ]
Britton, G. B. [1 ]
Rao, K. S. [1 ]
机构
[1] Inst Sci Res & Technol Serv INDICASAT AIP, Ctr Neurosci, City Of Knowledge, Panama
[2] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA
[3] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA
[4] Acharya Nagarjuna Univ, Dept Biotechnol, Guntur, India
关键词
alpha-Syn; AGEs; Lewy body; Neurodegeneration; PD; END-PRODUCTS AGES; CROSS-LINKING; OXIDATIVE STRESS; INHIBITS FIBRILLATION; CELL-DEATH; IN-VITRO; BINDING; PHOSPHORYLATION; MEMBRANE; BETA;
D O I
10.1007/s12035-012-8328-z
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The toxicity of alpha-synuclein in the neuropathology of Parkinson's disease which includes its hallmark aggregation has been studied scrupulously in the last decade. Although little is known regarding the normal functions of alpha-synuclein, its association with membrane phospholipids suggests its potential role in signaling pathways. Following extensive evidences for its nuclear localization, we and others recently demonstrated DNA binding activity of alpha-synuclein that modulates its conformation as well as aggregation properties. Furthermore, we also underscored the similarities among various amyloidogenic proteins involved in neurodegenerative diseases including amyloid beta peptides and tau. Our more recent studies show that alpha-synuclein is glycated and glycosylated both in vitro and in neurons, significantly affecting its folding, oligomeric, and DNA binding properties. Glycated alpha-synuclein causes increased genome damage both via its direct interaction with DNA and by increased generation of reactive oxygen species as glycation byproduct. In this review, we discuss the mechanisms of glycation and other posttranslational modifications of alpha-synuclein, including phosphorylation and nitration, and their role in neuronal death in Parkinson's disease.
引用
收藏
页码:525 / 536
页数:12
相关论文
共 92 条
[11]  
Cabin DE, 2002, J NEUROSCI, V22, P8797
[12]   α-synuclein cooperates with CSPα in preventing neurodegeneration [J].
Chandra, S ;
Gallardo, G ;
Fernández-Chacón, R ;
Schlüter, OM ;
Südhof, TC .
CELL, 2005, 123 (03) :383-396
[13]   Ribosylation Rapidly Induces α-Synuclein to Form Highly Cytotoxic Molten Globules of Advanced Glycation End Products [J].
Chen, Lan ;
Wei, Yan ;
Wang, Xueqing ;
He, Rongqiao .
PLOS ONE, 2010, 5 (02)
[14]   Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease [J].
Choei, H ;
Sasaki, N ;
Takeuchi, M ;
Yoshida, T ;
Ukai, W ;
Yamagishi, S ;
Kikuchi, S ;
Saito, T .
ACTA NEUROPATHOLOGICA, 2004, 108 (03) :189-193
[15]   Nε-(carboxymethyl)lysine linkage to α-synuclein and involvement of advanced glycation end products in α-synuclein deposits in an MPTP-intoxicated mouse model [J].
Choi, Yeong-Gon ;
Lim, Sabina .
BIOCHIMIE, 2010, 92 (10) :1379-1386
[16]   Advanced glycation end products, diabetes, and the brain [J].
Coker, Laura H. ;
Wagenknecht, Lynne E. .
NEUROLOGY, 2011, 77 (14) :1326-1327
[17]   Lipid droplet binding and oligomerization properties of the Parkinson's disease protein α-synuclein [J].
Cole, NB ;
Murphy, DD ;
Grider, T ;
Rueter, S ;
Brasaemle, D ;
Nussbaum, RL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (08) :6344-6352
[18]   Cytosolic O-glycosylation is abundant in nerve terminals [J].
Cole, RN ;
Hart, GW .
JOURNAL OF NEUROCHEMISTRY, 2001, 79 (05) :1080-1089
[19]   Phosphorylation does not prompt, nor prevent, the formation of α-synuclein toxic species in a rat model of Parkinson's disease [J].
da Silveira, Samareh Azeredo ;
Schneider, Bernard L. ;
Cifuentes-Diaz, Carmen ;
Sage, Daniel ;
Abbas-Terki, Toufik ;
Iwatsubo, Takeshi ;
Unser, Michael ;
Aebischer, Patrick .
HUMAN MOLECULAR GENETICS, 2009, 18 (05) :872-887
[20]   Evidence of oxidative stress in the neocortex in incidental Lewy body disease [J].
Dalfó, E ;
Portero-Otín, M ;
Ayala, V ;
Martínez, A ;
Pamplona, R ;
Ferrer, I .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2005, 64 (09) :816-830